99 related articles for article (PubMed ID: 27142123)
1. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis.
Xu KY; Shameem R; Wu S
Acta Oncol; 2016; 55(9-10):1196-1203. PubMed ID: 27142123
[TBL] [Abstract][Full Text] [Related]
2. Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials.
Shameem R; Hamid MS; Wu S
Anticancer Res; 2015 Apr; 35(4):2333-40. PubMed ID: 25862897
[TBL] [Abstract][Full Text] [Related]
3. Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.
Garcia CA; Wu S
Cancer Invest; 2016 Nov; 34(10):521-530. PubMed ID: 27791402
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
6. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
Xu J; Tian D
Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
[TBL] [Abstract][Full Text] [Related]
7. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.
Ramirez-Fort MK; Case EC; Rosen AC; Cerci FB; Wu S; Lacouture ME
Am J Clin Oncol; 2014 Jun; 37(3):266-71. PubMed ID: 23241507
[TBL] [Abstract][Full Text] [Related]
8. Metabolic complications with the use of mTOR inhibitors for cancer therapy.
Sivendran S; Agarwal N; Gartrell B; Ying J; Boucher KM; Choueiri TK; Sonpavde G; Oh WK; Galsky MD
Cancer Treat Rev; 2014 Feb; 40(1):190-6. PubMed ID: 23684373
[TBL] [Abstract][Full Text] [Related]
9. Risk of fatigue in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):477-86. PubMed ID: 25665062
[TBL] [Abstract][Full Text] [Related]
10. Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors.
Kaymakcalan MD; Je Y; Sonpavde G; Galsky M; Nguyen PL; Heng DY; Richards CJ; Choueiri TK
Br J Cancer; 2013 Jun; 108(12):2478-84. PubMed ID: 23736025
[TBL] [Abstract][Full Text] [Related]
11. Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.
Peng L; Zhou Y; Ye X; Zhao Q
Tumour Biol; 2015 Feb; 36(2):643-54. PubMed ID: 25281033
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
13. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Crit Rev Oncol Hematol; 2013 Oct; 88(1):30-41. PubMed ID: 23830806
[TBL] [Abstract][Full Text] [Related]
14. Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Ruiz-Schutz VC; Gomes LM; Mariano RC; de Almeida DVP; Pimenta JM; Dal Molin GZ; Kater FR; Yamamura R; Correa Neto NF; Maluf FC; Schutz FA
Crit Rev Oncol Hematol; 2019 Sep; 141():163-173. PubMed ID: 31306986
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
16. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: a pooled analysis of 18 randomized controlled trials.
Cui R; Chu L; Liu ZQ; Xiao YY; Zhu XL; Chen YJ; Xu Q
Int J Cancer; 2015 Feb; 136(4):936-44. PubMed ID: 24975040
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
[TBL] [Abstract][Full Text] [Related]
20. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
